ATE374251T1 - Zusammensetzungen zur gentherapie von diabetes - Google Patents

Zusammensetzungen zur gentherapie von diabetes

Info

Publication number
ATE374251T1
ATE374251T1 AT00916679T AT00916679T ATE374251T1 AT E374251 T1 ATE374251 T1 AT E374251T1 AT 00916679 T AT00916679 T AT 00916679T AT 00916679 T AT00916679 T AT 00916679T AT E374251 T1 ATE374251 T1 AT E374251T1
Authority
AT
Austria
Prior art keywords
compositions
diabetes
gene therapy
expressed
insulin
Prior art date
Application number
AT00916679T
Other languages
English (en)
Inventor
Matthew J During
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Application granted granted Critical
Publication of ATE374251T1 publication Critical patent/ATE374251T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00916679T 1999-02-19 2000-02-22 Zusammensetzungen zur gentherapie von diabetes ATE374251T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12097599P 1999-02-19 1999-02-19

Publications (1)

Publication Number Publication Date
ATE374251T1 true ATE374251T1 (de) 2007-10-15

Family

ID=22393646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916679T ATE374251T1 (de) 1999-02-19 2000-02-22 Zusammensetzungen zur gentherapie von diabetes

Country Status (8)

Country Link
US (1) US6503887B1 (de)
EP (1) EP1153131B1 (de)
JP (1) JP2002540175A (de)
AT (1) ATE374251T1 (de)
AU (1) AU777988B2 (de)
CA (1) CA2364417C (de)
DE (1) DE60036537T2 (de)
WO (1) WO2000057921A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719950B2 (en) * 1995-06-07 2000-05-18 Yale University Oral delivery of adeno-associated viral vectors
CN102151337B (zh) 2000-03-13 2014-03-12 恩根尼公司 调节消化道蛋白表达的组合物和方法
WO2002050264A2 (en) * 2000-12-18 2002-06-27 Wyeth Promoters and recombinant expression constructs
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
FR2852247A1 (fr) * 2003-03-11 2004-09-17 Centre Nat Rech Scient Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
EP2001875A2 (de) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase-aktivatoren
AU2007285472B2 (en) 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
EP2049518B1 (de) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
EP2625270A4 (de) * 2010-10-08 2014-02-26 Univ Putra Malaysia Upm Glp-1-promoter-vermittelte insulinexpression zur behandlung von diabetes
US10696946B2 (en) 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
JP6754361B2 (ja) * 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
EP3371209A1 (de) 2015-11-06 2018-09-12 The Board of Trustees of the University of Illinois Chimäre ox40l-jagged-1-polypeptide und verwendungen davon
IL263874B2 (en) 2016-06-22 2025-02-01 David Klatzmann Genetically modified T lymphocytes
WO2018127702A1 (en) 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
EP3976087A1 (de) * 2019-05-31 2022-04-06 Universitat Autònoma De Barcelona Insulingentherapie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837693A (en) 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
FR2732978B1 (fr) 1995-04-14 1997-05-30 Inst Nat Sante Rech Med Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
US5646034A (en) 1995-06-07 1997-07-08 Mamounas; Michael Increasing rAAV titer
AU719950B2 (en) 1995-06-07 2000-05-18 Yale University Oral delivery of adeno-associated viral vectors
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
ES2355588T3 (es) * 1997-03-14 2011-03-29 The Children's Hospital Of Philadelphia Composiciones para uso en terapia génica para el tratamiento de hemofilia.

Also Published As

Publication number Publication date
DE60036537D1 (de) 2007-11-08
EP1153131B1 (de) 2007-09-26
EP1153131A2 (de) 2001-11-14
AU3774700A (en) 2000-10-16
WO2000057921A2 (en) 2000-10-05
US6503887B1 (en) 2003-01-07
WO2000057921A3 (en) 2001-01-04
DE60036537T2 (de) 2008-06-19
CA2364417C (en) 2013-11-05
AU777988B2 (en) 2004-11-11
JP2002540175A (ja) 2002-11-26
CA2364417A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2021087296A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
WO2020186207A3 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
AR047392A1 (es) Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
WO2003023000A3 (en) Linear dna fragments for gene expression
WO2004016224A3 (en) Antisense modulation of vegf co-regulated chemokine-1 expression
WO2004074450A8 (en) Combination therapy for treating protein deficiencies
EP1327449A4 (de) Mittel zur behandlung von ischämischen erkrankungen
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2020163743A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2023197001A3 (en) Compositions and methods for treating liver diseases with sirnas targeting cideb
IL141984A0 (en) Akt nucleic acids, polypeptides, and uses thereof
WO2004076626A3 (en) Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
WO2005014607A3 (en) Antisense modulation of stearoyl-coa desaturase expression
EP1712243A4 (de) Gentherapie gegen tumoren mit minus-strang-rna-virusvektoren, die für immunstimulatorische zytokine codieren
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2003012031A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2021131944A8 (ja) 癌遺伝子治療薬
WO2001081404A3 (en) INDUCIBLE PLASMID VECTOR ENCODING TGF-β AND USES THEREOF
AU2606000A (en) Antisense modulation of x-linked inhibitor of apoptosis expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties